FASN and neoplasm: Although intervention strategies targeting lipid metabolism (such as the fatty acid synthase inhibitor TVB-2640) have shown potential in clinical trials, their efficacy is limited by tumor heterogeneity, metabolic pathway redundancy, and the complexity of host-microbiome interactions (25, 26).